The evolving therapy of DLBCL: Bispecific antibodies

11Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Bispecific antibodies have been successfully introduced into the management of relapsed or refractory B-cell lymphomas, including DLBCL. Phase 1 studies of the different CD3/CD20 bispecifics have shown manageable safety profile and promising activity in a range of B-cell lymphomas, and recent phase 2 studies confirm the favourable safety and show frequent and durable complete responses even in heavily pre-treated and high-risk patients. This paper discusses the future potential role of these new agents as single agents and in combinations, and their position in the current and future treatment landscape, also in relation to chimeric antigen receptor T-cell therapy.

Cite

CITATION STYLE

APA

Hutchings, M. (2023, June 1). The evolving therapy of DLBCL: Bispecific antibodies. Hematological Oncology. John Wiley and Sons Ltd. https://doi.org/10.1002/hon.3154

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free